A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer

References

• Are C, Rajaram S, Are M, Raj H, Anderson BO, Chaluvarya Swamy R, Vijayakumar M, Song T, Pandey M, Edney JA, et al. A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol 2013; 107:221 - 6; http://dx.doi.org/10.1002/jso.23248; PMID: 22926725
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893 - 917; http://dx.doi.org/10.1002/ijc.25516; PMID: 21351269
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22:777 - 84; http://dx.doi.org/10.1200/JCO.2004.08.001; PMID: 14990632
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22:785 - 94; http://dx.doi.org/10.1200/JCO.2004.07.215; PMID: 14990633
   PubMed Web of Science ®Google Scholar
• Davies AM, Ho C, Lara PN Jr., Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 7:385 - 8; http://dx.doi.org/10.3816/CLC.2006.n.021; PMID: 16800963
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:5080 - 7; http://dx.doi.org/10.1200/JCO.2008.21.5541; PMID: 19738125
   PubMed Web of Science ®Google Scholar
• Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 2013; 14:777 - 86; http://dx.doi.org/10.1016/S1470-2045(13)70254-7; PMID: 23782814
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543 - 51; http://dx.doi.org/10.1200/JCO.2007.15.0375; PMID: 18506025
   PubMed Web of Science ®Google Scholar
• Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:3217 - 24; http://dx.doi.org/10.1200/JCO.2008.20.9114; PMID: 19433683
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al, TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892 - 9; http://dx.doi.org/10.1200/JCO.2005.02.840; PMID: 16043829
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545 - 52; http://dx.doi.org/10.1200/JCO.2005.05.1474; PMID: 17442998
   PubMed Web of Science ®Google Scholar
• Lara PN Jr., Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR, Southwest Oncology Group. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008; 26:463 - 7; http://dx.doi.org/10.1200/JCO.2007.13.0344; PMID: 18202421
   PubMed Web of Science ®Google Scholar
• Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12:6049 - 55; http://dx.doi.org/10.1158/1078-0432.CCR-06-0260; PMID: 17062680
   PubMed Web of Science ®Google Scholar
• Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, van Tinteren H, Hoekstra OS, Pruim J, Brans B, et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 2011; 22:559 - 66; http://dx.doi.org/10.1093/annonc/mdq391; PMID: 20702788
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, et al, SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521 - 9; http://dx.doi.org/10.1016/S1470-2045(10)70112-1; PMID: 20493771
   PubMed Web of Science ®Google Scholar
• Juhász E, Kim JH, Klingelschmitt G, Walzer S. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer 2013; 49:1205 - 15; http://dx.doi.org/10.1016/j.ejca.2012.11.006; PMID: 23477998
   PubMed Web of Science ®Google Scholar
• Wu YL, Kim JH, Park K, Zaatar A, Klingelschmitt G, Ng C. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer 2012; 77:339 - 45; http://dx.doi.org/10.1016/j.lungcan.2012.03.012; PMID: 22494567
   PubMed Web of Science ®Google Scholar
• Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:4113 - 20; http://dx.doi.org/10.1200/JCO.2010.31.8162; PMID: 21969500
   PubMed Web of Science ®Google Scholar
• Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, Gopalakrishna P, Cappuzzo F, SATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012; 23:388 - 94; http://dx.doi.org/10.1093/annonc/mdr125; PMID: 21610154
   PubMed Web of Science ®Google Scholar
• Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, et al, INFORM investigators. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012; 13:466 - 75; http://dx.doi.org/10.1016/S1470-2045(12)70117-1; PMID: 22512843
   PubMed Web of Science ®Google Scholar
• Reckamp KL. Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?. Lancet Oncol 2012; 13:435 - 6; http://dx.doi.org/10.1016/S1470-2045(12)70157-2; PMID: 22512846
   PubMed Web of Science ®Google Scholar
• Piperdi B, Ling YH, Kroog G, Perez-Soler R. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/Mb) on human NSCLC cell lines in vitro. J Clin Oncol 2004; 22:14S 7028
   Google Scholar
• Mahaffey CM, Davies AM, Lara PN Jr., Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007; 8:548 - 53; http://dx.doi.org/10.3816/CLC.2007.n.041; PMID: 18186959
   PubMed Web of Science ®Google Scholar
• Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30:3516 - 24; http://dx.doi.org/10.1200/JCO.2011.39.9782; PMID: 22949150
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer 2012; 77:346 - 52; http://dx.doi.org/10.1016/j.lungcan.2012.03.011; PMID: 22534669
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans SJ, Visseren-Grul C, Peterson P. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 2009; 45:2298 - 303; http://dx.doi.org/10.1016/j.ejca.2009.04.033; PMID: 19473833
   PubMed Web of Science ®Google Scholar
• Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, et al. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010; 14:Suppl 1 47 - 53; PMID: 20507803
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, et al. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013; 14:1545 - 58; http://dx.doi.org/10.1517/14656566.2013.802774; PMID: 23683110
   PubMed Web of Science ®Google Scholar
• Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24:2371 - 6; http://dx.doi.org/10.1093/annonc/mdt205; PMID: 23723294
   PubMed Web of Science ®Google Scholar